Neurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences Inc (NBIX) tracked by StreetAlpha. NBIX reports earnings on Tue, Oct 27, 2026. The average 12-month price target from 15 analysts is $208.07, with a high of $253.00 and a low of $170.00. Analyst consensus is Strong Buy, based on the latest ratings from 15 firms (13 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in NBIX, 67% of them bullish and 33% bearish.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 15 analysts who set a price target on NBIX in the past 90 days. The average target is $208.07, with a high of $253.00 and a low of $170.00.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 29 | UBS | Maintained | Buy | $214 |
| Sep 11 | Morgan Stanley | Target raised | Hold | $182 → $183 |
| Sep 8 | RBC Capital | Reiterated | Buy | $198 |
| Sep 3 | Citigroup | Target raised | Buy | $249 → $253 |
| Aug 13 | Morgan Stanley | Target lowered | Hold | $196 → $182 |
Whale Options Flow
90DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NBIX is in one of them and how their past NBIX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NBIX in an article yet. Here's the latest on the wider market.
For informational purposes only. Not financial advice. Options flow and dark pool data are delayed and may be incomplete.